Stock Ratings / Health Care / DRMA / earnings

MDCX (35) NRSN (38) XTLB (47) NCNA (56) ⌘ Pro Terminal →

Dermata Therapeutics Inc. (DRMA) Next Earnings Date & Expected ±12.5% Move

$0.84 -3.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Dermata Therapeutics Inc. (DRMA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $4.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRMA)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.10 Expected Swing

MODEL EARNINGS SETUP GAUGE

DRMA Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (43/100)Model Risk Weight (57/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$7.6M	-$7.8M	52%
FY 2024	2024-12-31	$0	-$12.3M	-$11.2M	52%
FY 2023	2023-12-31	$0	-$7.8M	-$6.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRMA)

✓Walkthrough of DRMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DRMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.69%📐 HORIZONTAL RANGE

2026-10-30O $0.80H $0.84L $0.76C $0.84VOL 61.7K

RES: $1.97SUP: $0.52SMA50: $1.10SMA200: $1.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRMA Butterfly Map → + Track DRMA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DRMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DRMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRMA)

Health Care Rank #564 of 1016 ⚔️ MDCX vs DRMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRMA vs. MDCX, NRSN, XTLB, NCNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dermata Therapeutics Inc. (DRMA) ranks #564 by composite RQD confidence (43/100, grade D-) and #958 by equity capitalization ($4.2M). Within this direct 5-issuer industry benchmark cohort, DRMA leads on earnings valuation at N/A trailing P/E, while DRMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NCNA currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with DRMA at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DRMA ACTIVE Dermata Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.84%	$4.2M	Benchmark Subject
MDCX Medicus Pharma Ltd.	D-	35/100	—	—	-35.0%	-13.31%	$4.1M	/mdcx-vs-drma →
NRSN NeuroSense Therapeutics Ltd.	D-	38/100	—	—	-35.0%	-9.75%	$4.0M	/nrsn-vs-drma →
XTLB XTL Biopharmaceuticals Ltd.	D	47/100	—	—	—	-12.44%	$4.3M	/xtlb-vs-drma →
NCNA NuCana plc	D+	56/100	—	—	—	-3.26%	$4.3M	/ncna-vs-drma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001853816

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dermata Therapeutics Inc. (DRMA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.6M, operating cash flow of -$7.8M, and free cash flow of -$7.8M (+30.1% YoY). On the balance sheet, DRMA closed FY2025 with $7.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$7.6M	-$7.8M	-$7.8M	$7.9M	—
FY2024 (FY)	2024-12-31	$0	-$12.3M	-$11.2M	-$11.2M	$3.5M	—
FY2023 (FY)	2023-12-31	$0	-$7.8M	-$6.4M	-$6.4M	—	—

3. DRMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Dermata Therapeutics Inc. (NASDAQ: DRMA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.84 (-3.84% 1D, market cap $4.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DRMA ranks #564 in composite RQD confidence.

How does DRMA compare to MDCX and NRSN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DRMA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MDCX (Medicus Pharma Ltd.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $4.1M) and NRSN (NeuroSense Therapeutics Ltd.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, DRMA leads on earnings multiple (N/A) while DRMA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DRMA?

Per DRMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853816), Dermata Therapeutics Inc. generated $0 in revenue, -$7.6M in net income, and -$7.8M in free cash flow against $7.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DRMA trading relative to its 50-day, 200-day, and 52-week technical levels?

DRMA last traded at $0.84 (-3.84% on volume of 32,224 shares), positioning the stock -23.64% below its 50-day simple moving average ($1.10) and -36.36% below its 200-day simple moving average ($1.32). Across its 52-week range of $0.60 to $4.66, DRMA sits at the 5.9% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.94).